Anavex Life Sciences Corp (AVXL)

[seventhwave]

biochecker4, i agree with your overall assessment on institutional holders but wouldn't read too negatively into Park West's trimming given AVXL's context in their overall portfolio.
Alzheimer's is a 'show me' indication and while the broad MOA is established, the outperformance of A2-73 to other S1R's is still unknown IMO.
No money mgr is expected to risk one's career and reputation by going out on a limb. If AVXL trials are successful, there will be plenty of time & oppty for mgrs to pile in and that's what they do.
Case in point AXSM: (i'm fervently praying AVXL chart follows AXSM which is currently a 10x bagger and still under 1bn mktcap.)
AXSM failed multiple trials until they struck big in MDD. Stock popped to 6+ from where we are currently and mmgrs have subsequently obliged and have come out looking like stars.
Also check out SAGE and even Avanir which got acquired. Success in neuro indications usually reaps big rewards.
Our fate hinges on trial outcome & then financing & leadership; everything else will take care of itself.